The global head and neck squamous cell carcinoma market is set for steady growth, driven by advancements in treatment options, increasing awareness of early cancer detection, and rising demand for ...

Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates overall response rate and safety profile consistent with the 1500mg QW ...

Keytruda plus platinum-based chemotherapy was found to be both safe and efficacious in treating penile squamous cell carcinoma (PSCC), according to findings from the phase 2 HERCULES trial presented ...

Drug approvals this year have reflected the trend in clinical development of biologics shifting from intravenous to ...

The main market opportunities for PD-1 Resistant Head and Neck Cancer include developing combination therapies and next-gen ...

Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free ...

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative ...

Bicara Therapeutics announced the publication of an abstract with early data from a Phase 1b expansion cohort evaluating 750mg of ficerafusp alfa ...

Regeneron Pharmaceuticals’ Libtayo (cemiplimab) has received approval from the European Commission for the adjuvant treatment ...

Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced that Palmetto GBA, the Medicare Administrative Contractor that administers the Molecular ...